AUSTIN, TX—Duloxetine, pregabalin, and duloxetine + gabapentin were found to be safe and tolerable for the treatment of diabetic peripheral neuropathic pain, according to results presented today at ...

The FDA has approved duloxetine (Cymbalta) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic low-back pain. Several recent randomized trials have evaluated ...

To assess the effectiveness of duloxetine in addition to usual care in patients with chronic osteoarthritis (OA) pain. The cost-effectiveness and whether the presence of symptoms of centralized pain ...

August 20, 2010 — A US Food and Drug Administration (FDA) advisory committee has voted 8 to 6 in favor of Eli Lilly's request to broaden the indication for its antidepressant drug duloxetine (Cymbalta ...

Adherence to aromatase inhibitor (AI) therapy for early-stage breast cancer is limited by AI-associated musculoskeletal symptoms (AIMSS). Duloxetine is US Food and Drug Administration approved for ...

The Food and Drug Administration recently approved Cymbalta (duloxetine hydrochloride) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain. The ...

CHICAGO (Reuters) - Eli Lilly and Co said on Friday it withdrew an application to market its anti-depressant Cymbalta for the management of chronic pain because U.S. health regulators raised questions ...

NEW YORK (Reuters) - Eli Lilly said on Thursday U.S. regulators approved the use of Cymbalta, its blockbuster anti-depressant drug, for chronic musculoskeletal pain, including lower back pain and ...

The U.S. Food and Drug Administration has approved Cymbalta for chronic back pain and osteoarthritis pain, according to a FDA news release. Cymbalta, which was first used to treat major depressive ...

A popular antidepressant, often known by the brand name Cymbalta, was recalled last week due to the presence of a potentially cancer-causing chemical. More than 233,000 bottles of duloxetine capsules ...